Drugs / INF108F
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05793112 | Sep 2023 → Sep 2024 | food protein-induced allergic proctocolitis | Massachusetts General Hospital | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INF108F | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05793112 ↗ |
| Modality | Other / unclassified | “INF108F probiotic” NCT05793112 ↗ |
| Route | Oral | “Oral suspension” NCT05793112 ↗ |